It would be worthwhile, therefore, to study the involvement of Akt downstream of CD133 in ovarian cancer and, in particular, to assess whether targeting Akt signalling affects the self-renewal and tumorigenic potential of CD133-positive OCSC. This evidence concerns the gene PROM1 and ovarian carcinoma.